Phase 2 Vitiligo Trial, Recruiting NCT07437560 Sponsor: Hudson Biotech Condition: Vitiligo
Back to Vitiligo

Phase 2 Vitiligo Trial, Recruiting

NCT07437560
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are an adult between 18 and 65 years old and are able to give your own consent to participate.
  • You have been diagnosed with nonsegmental vitiligo (a common form where patches appear in a scattered pattern) that has been stable — meaning no new patches and no existing patches getting bigger — for at least 6 months before the screening visit.
  • Your vitiligo affects between 3% and 20% of your total body surface area, and you have at least two patches that can be clearly measured and photographed.
  • You are willing to receive a specific type of light therapy called NB-UVB as part of the study, and to stop using other vitiligo treatments during the trial.
  • If you are someone who could become pregnant, you agree to use effective birth control throughout the study and for a set period after your last dose.

Who may not be able to join:

  • Your vitiligo is mainly the segmental type (patches on one side of the body) or your condition has been getting worse quickly in the past 6 months.
  • You have taken certain medicines that affect the immune system — such as immunosuppressants, steroid tablets, or JAK inhibitor drugs — within the past 8 weeks (the exact timeframe may depend on the specific medicine).
  • You have applied certain skin creams (calcineurin inhibitors or steroid creams) to the patches being studied within the past 2 weeks.
  • You have previously been treated with afamelanotide or melanotan (including Melanotan II) within the past 6 months.
  • You have a history of melanoma, a condition called dysplastic nevus syndrome, or other serious skin cancers that need close monitoring, as decided by the study doctor.
  • You have significantly uncontrolled high blood pressure, heart or blood vessel disease, or any other health condition that the study doctor believes could put you at higher risk with this type of treatment.
  • You are currently pregnant or breastfeeding.
  • You have a known allergy or sensitivity to any ingredients in the study treatment.
  • You have taken part in another clinical trial involving a treatment within the past 30 days before your screening visit.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 13076790030

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Hudson Biotech
Registry
ClinicalTrials.gov
Start date
2 February 2026
Est. completion
14 February 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change from baseline in Vitiligo Area Scoring Index (VASI) total score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov